Danish biotech company gets second wave of investor support  

ACE BioSciences announces a new round of funding from existing investors worth DKK 46 million

Danish biotech company ACE BioSciences A/S has announced a new round of funding from existing investors worth DKK 46 million (USD 6.3 million) to support its work in the area of infectious diseases. The company started up in 2001 funded by a DKK 70 million (USD 9.6 million) investment from BankInvest A/S, P/S Dansk Innovationsinvestering and the Danish Growth Fund. Despite current conditions in the biotech sector, ACE Biosciences has proved its capacity to advance, achieving milestones ahead of schedule. The news is reoported by business daily Erhvervsbladet.


ACE BioSciences' research is based on a broad biotechnology platform integrating biology and analytical chemistry. Protein Interaction Technology enables the company to discover and validate novel protein targets in a wide range of infectious bacteria and fungi. ACE BioSciences is collaborating with the biotechnological industry, the pharmaceutical industry and academia to improve the technology platform and use its validated targets to develop new therapeutics.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×